CELU
Celularity Inc.
There isn't enough reported data to score CELU yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CELU Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Unavailable |
CELU's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CELU PE Valuation
CELU has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CELU Forward outlook
There aren't enough analyst estimates for CELU to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CELU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.69 | +$1.48 |
| Q1 2026 | -$2.73 | -$0.28 |
| Q4 2025 | -$3.59 | -$0.95 |
CELU is still losing money, but far less than before: $1.69 per share over the past year, against $9.60 at its worst in late 2023.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CELU in the latest year-over-year earnings comparison.
CELU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.4M | -5.3% |
| Q1 2026 | $3.8M | -66% |
| Q4 2025 | $4.1M | -77% |
| Q3 2025 | $5.3M | -43% |
| Q2 2025 | $5.7M | -53% |
| Q1 2025 | $11.4M | -22% |
| Q4 2024 | $18.1M | +50% |
| Q3 2024 | $9.3M | +146% |
CELU's revenue has slid since its 2024 peak: $5M last quarter, down 5.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -78% | +199 points |
| Q1 2026 | -263% | -172 points |
| Q4 2025 | -537% | -486 points |
| Q3 2025 | -244% | -120 points |
| Q2 2025 | -277% | -193 points |
| Q1 2025 | -92% | -42 points |
| Q4 2024 | -51% | -161 points |
| Q3 2024 | -124% | +2498 points |
CELU's operating margin was −78% last quarter, up 199 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over CELU on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CELU on profitability, with a higher operating margin.
CELU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$5.1M | -432% |
| Q4 2024 | $1.5M | +$6.5M |
| Q3 2024 | -$179K | +$8.4M |
| Q2 2024 | -$3.5M | +$7.6M |
| Q1 2024 | -$4.4M | +$10.8M |
| Q4 2023 | -$4.9M | +$25.4M |
| Q3 2023 | -$8.6M | +$30.7M |
| Q2 2023 | -$11.1M | +$26.7M |
CELU has the stronger cash trend. Its trailing FCF is up 93% versus its history, compared with NVO at down 14%.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
CELU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.2% | -955K shares |
| 1 year | +25% | +5.8M shares |
| 3 years | +89% | +13.8M shares |
| 5 years | +3561% | +28.5M shares |
CELU has 29M diluted shares, up 25% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CELU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CELU Net Leverage
CELU's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CELU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.3 | Neutral |
| Stochastic | 6.1 | Oversold |
CELU's weekly RSI is 39 (neutral) and its Stochastic is 6 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CELU PE vs Healthcare Sector
| Metric | CELU | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CELU has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CELU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.13 | 40% below |
| 20 week MA | $1.04 | 35% below |
| 50 week MA | $1.12 | 39% below |
| 100 week MA | $1.63 | 58% below |
| 200 week MA | $2.85 | 76% below |
CELU is in a downtrend: it's below all five of its weekly moving averages, and 76% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over CELU on trend strength, trading above more of its moving averages.
CELU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $99.5 | $118.0 | +19% |
| 2021 | $118.0 | $47.0 | -60% |
| 2022 | $47.0 | $11.5 | -76% |
| 2023 | $11.5 | $2.47 | -79% |
| 2024 | $2.47 | $2.24 | -9.3% |
| 2025 | $2.24 | $1.34 | -40% |
| 2026 YTD | $1.34 | $0.68 | -49% |
CELU has finished five years in a row lower, and it's down 49% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over CELU on returns for 2026, with the stronger performance.